Reporting any (1) serious, unexpected suspected adverse reactions, (2) findingsfrom other clinical, animal, or in-vitro studies that suggest significant human risk,and (3) a clinically important increase in the rate of a serious suspected adversereaction to this Division and to all investigators no later than 15 calendar days afterdetermining that the information qualifies for reporting [21 CFR 312.32(c)(1)].Submit 15-day reports to FDA electronically in eCTD format via the ESG; and